Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/73787
Título: Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study
Autores/as: Carmona-Bayonas, Alberto
Jiménez-Fonseca, Paula
Echaburu, Juan Virizuela
Antonio, Maite
Font, Carme
Biosca, Mercè
Ramchandani, Avinash
Martínez, Jerónimo
Cubero, Jorge Hernando
Espinosa, Javier
De Castro, Eva Martínez
Ghanem, Ismael
Beato, Carmen
Blasco, Ana
Garrido, Marcelo
Bonilla, Yaiza
Mondéjar, Rebeca
Lanza, María Ángeles Arcusa
Manrique, Isabel Aragón
Manzano, Aránzazu
Sevillano, Elena
Castañón, Eduardo
Cardona, Mercé
Martín, Elena Gallardo
Armillas, Quionia Pérez
Lasheras, Fernando Sánchez
De La Peña, Francisco Ayala
Clasificación UNESCO: 320101 Oncología
Fecha de publicación: 2015
Publicación seriada: Journal of Clinical Oncology 
Resumen: Purpose: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections. Patients and Methods: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We ntegrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE. Results: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC). Conclusion: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes.
URI: http://hdl.handle.net/10553/73787
ISSN: 0732-183X
DOI: 10.1200/JCO.2014.57.2347
Fuente: Journal of Clinical Oncology [ISSN 0732-183X], v. 33 (5), p. 465-471, (Febrero 2015)
Colección:Artículos
Vista completa

Citas SCOPUSTM   

111
actualizado el 21-abr-2024

Visitas

52
actualizado el 30-dic-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.